Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...

It’s not enough to ask what the technology can theoretically do. Leaders should press vendors on precisely what the workflow ...